Literature DB >> 28616585

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody.

Shi Hu1.   

Abstract

Epidermal growth factor receptor (EGFR) is a widely recognized target for tumors, but resistance is commonly reported. Recently, we reported that dual targeting of EGFR and NOTCH2/3 receptors with antibody CT16 showed a strong anti-stem effect both in vitro and in vivo to overcome resistance of EGFR inhibitors and radiation.

Entities:  

Keywords:  Bispecific antibodies; EGFR; Notch recptors; Targeted Therapy

Year:  2017        PMID： 28616585      PMCID： PMC5462514          DOI： 10.1080/23723556.2017.1308851

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Authors:  K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 2.  Metastasis: a question of life or death.

Authors:  Patrick Mehlen; Alain Puisieux
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

Review 3.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

4.  Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.

Authors:  Shi Hu; Wenyan Fu; Tian Li; Qingning Yuan; Feifei Wang; Gaojian Lv; Yuanyuan Lv; Xiaoyan Fan; Yafeng Shen; Fangxing Lin; Ying Tang; Xuting Ye; Yongji Yang; Changhai Lei
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

Review 5.  Targeting notch signaling pathway in cancer: clinical development advances and challenges.

Authors:  Naoko Takebe; Dat Nguyen; Sherry X Yang
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

6.  Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

Authors:  Shi Hu; Wenyan Fu; Weihao Xu; Yang Yang; Melissa Cruz; Sandra D Berezov; Daniel Jorissen; Hiroaki Takeda; Wangdong Zhu
Journal:  Cancer Res       Date:  2014-11-04       Impact factor: 12.701

Review 7.  Cancer stem cells: The root of tumor recurrence and metastases.

Authors:  Claudia Peitzsch; Anna Tyutyunnykova; Klaus Pantel; Anna Dubrovska
Journal:  Semin Cancer Biol       Date:  2017-02-28       Impact factor: 15.707

8.  Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.

Authors:  Shi Hu; Haibin Dai; Tian Li; Ying Tang; Wenyan Fu; Qingning Yuan; Feifei Wang; Gaojian Lv; Yuanyuan Lv; Xiaoyan Fan; Sheng Zhang; Ruobing Jin; Yafeng Shen; Fangxing Lin; Xuting Ye; Min Ding; Yongji Yang; Changhai Lei
Journal:  Cancer Lett       Date:  2016-08-26       Impact factor: 8.679

9.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Authors:  Xiaoxian Li; Michael T Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

10.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.